Human Mesenchymal Stem Cells Suppress the Stretch–Induced Inflammatory miR-155 and Cytokines in Bronchial Epithelial Cells

Current research in pulmonary pathology has focused on inflammatory reactions initiated by immunological responses to allergens and irritants. In addition to these biochemical stimuli, physical forces also play an important role in regulating the structure, function, and metabolism of the lung. Hyperstretch of lung tissues can contribute to the inflammatory responses in asthma, but the mechanisms of mechanically induced inflammation in the lung remain unclear. Our results demonstrate that excessive stretch increased the secretion of inflammatory cytokines by human bronchial epithelial cells (hBECs), including IL-8. This increase of IL-8 secretion was due to an elevated microRNA-155 (miR-155) expression, which caused the suppression of Src homology 2 domain–containing inositol 5-phosphatase 1 (SHIP1) production and the subsequent activation of JNK signaling. In vivo studies in our asthmatic mouse model also showed such changes in miR-155, IL-8, and SHIP1 expressions that reflect inflammatory responses. Co-culture with human mesenchymal stem cells (hMSCs) reversed the stretch-induced hBEC inflammatory responses as a result of IL-10 secretion by hMSCs to down-regulate miR-155 expression in hBECs. In summary, we have demonstrated that mechanical stretch modulates the homeostasis of the hBEC secretome involving miR-155 and that hMSCs can be used as a potential therapeutic approach to reverse bronchial epithelial inflammation in asthma.


Introduction
Physical forces, including shear stress and stretching force, influence the structure, function and metabolism of lung cells [1,2,3]. Cells in the respiratory airway are constantly exposed to mechanical stretches due to cyclic expansions and deflations of the lung. The lungs in asthma patients with increased respiration rates experience greater stretch beyond that during normal respiration [4,5]. Mechanical stretches regulate airway remodeling, and the high pressures associated with enhanced ventilation in vivo have been shown to modulate airway gene expression [6,7]. It has been demonstrated that mechanical stretch in vitro regulates epithelial signaling [8], gene expression [8], and pulmonary functions [9,10]. It has also been shown that asthma attacks can trigger deep inspirations with increases in amplitude and frequency and that the resulting hyperstretch tends to worsen the airway obstruction [11,12]. Ex vivo hyperstretching (2.56of basal tone) of human bronchi isolated from patients can cause myogenic and pulmonary inflammatory responses (e.g., epithelial release of leukotrienes) [13]. These studies suggest that hyperstretch play an important role in modulating pulmonary homeostasis.
Emerging information has revealed miRs as critical regulators of gene expression and hence many cellular functions in health and disease. Since miRs regulate 30% of human gene expression [14], the miR expression signatures can be employed as biomarkers for tissue functions and diseases. In airway cells, miR expression profiles can be regulated by multiple factors, including growth factors [15], inflammatory agents [16], mechanical force [17], and hypoxia [18]. miRs have been demonstrated to play critical roles in many inflammatory diseases and asthma [19,20], but the roles of miRs in regulating the mechanical pathobiology of the lung remain to be established.
Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells which were first discovered in bone marrow stroma as fibroblast-like non-hematopoietic stem cells [21]. These cells have the capacity to differentiate into multiple lineages, including osteoblasts, adipocytes, endothelial cells, myocytes, astrocytes, and hepatocytes [22,23,24,25,26]. hMSCs have been shown to play an important role in modulating the immune system and proposed to be a potential therapeutic modality for many clinical conditions, including inflammatory diseases [27,28,29,30,31]. Thus, hMSCs can be considered for usage as immunomodulators to rescue hyperstretch-induced inflammation in hBECs.
We have studied the mechanism by which hyperstretch induces hBEC inflammatory responses by utilizing an in vitro stretch system [32] with a frequency of 40 cycles/min (cpm) and an amplitude of 10% to mimic the in vivo pathological states [33]. We demonstrated that hyperstretch induces miR-155 to reduce SHIP1, leading to the activation of JNK and the consequential IL-8 secretion. The results were confirmed with the use of an OVA-induced asthmatic mouse model [34]. The in vivo studies on bronchoalveolar lavage and lung tissues from the asthmatic mice showed increased expressions of IL-8 and miR-155, and decreased expressions of IL-10 and SHIP1; these in vivo pulmonary inflammatory reactions are in agreement with the findings on hBECs under hyperstretch in vitro. Furthermore, we have shown that hMSCs can mitigate the miR-155-mediated inflammatory responses due to hyperstretch by using a hMSC/hBEC co-culture stretch system.

Stretching Experiments
We have created a device that generates equibiaxial stretch [32]. In each stretch chamber, a silicone membrane is secured to a polycarbonate holder by using a silicone rubber O-ring and positioned over a Teflon indenter. The cells were seeded onto fibronectin-coated stretch chambers, at a concentration of 40,000 cells per chamber with a surface area of 262 cm 2 . The chambers were assembled onto a mobile plate attached to a cam, which was rotated by a DC motor to generate a vertical sinusoidal displacement against the indenters, thus cyclically deforming the membranes. Stretch amplitude and frequency were controlled by varying the mobile plate displacement and motor speed. The hyperstretch experiments were performed with 10% area increase at a frequency of 40 cpm to mimic the in vivo pathological condition. Cells were incubated for 24 hours before the stretching experiments. Non-stretched cells culturing in the static chambers were used as controls.

Cytokine Array
Mouse and human cytokine Multi-Analyte ELISArray Kit (SABiosciences) were used to measure the cytokine production of IL1A, IL1B, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL17A and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in mouse BAL with or without OVA-treated, or supernatants of conditioned media of hBECs with or without stretch after 24 hours of culture. The arrays were performed according to the manufacturer's instructions. The absorbance levels of the cytokines were measured on a plate reader (Beckman Coulter DTX 880) at 450 nm. Sampling was performed in triplicates including standards. 12 arrays were used for each human and mouse experiment. Standard errors of the mean were calculated from three biological repeats.

OVA-induced Asthmatic Mouse Model
BALB/c mice were challenged with OVA over a period of 21-28 days as described previously [35,36]. In brief, the animals were sensitized by intraperitoneal injection of OVA (20 mg/100 ml), followed by intranasal challenge with 1% OVA in PBS every other day for 3-4 weeks. The OVA-induced responses were assessed by determining the cell counts and protein concentration in postmortem BAL fluid, and measuring the cytokine and IgE levels in serum [35,35]. All animal procedures were approved by the University of California San Diego Institutional Animal Care and Use Committee, and met guidelines of the National Institutes of Health.

Immunohistology Staining
The expression levels of SHIP and miR-155 in lung tissues were detected by immunostaining with a specific antibody for SHIP1 (Santa Cruz Biotechnology) and a specific probe, miRCURY LNA TM Detection probe, 250 pmol, 5-DIG and 3-DIG labeled, for mouse miR-155 (EXIQON). Negative control experiments omitting primary antibody and probe were included for each experiment (data not shown).

ELISA Assay
Conditioned media collected from stretch experiments or static controls were centrifuged to remove cell debris, and the volumes of the various samples were determined. The IL-8 and IL-10 concentrations in the media were measured with R&D ELISA kits. Briefly, 100 ml of the media were applied to the immunoplate precoated with anti-human or anti-mouse monoclonal antibody. Secondary detection antibody of each assay was then added to the immobilized IL-8 and IL-10 in the sample. The conjugation of anti-IL-8 and IL10 with their antigens was visualized using Avidin-HRP substrate. The arrays were performed according to the manufacturer's instructions. The absorbance levels of proteins were measured on a plate reader at 450 nm. Sampling was performed in triplicates.

Antibodies and Reagents
Mouse monoclonal antibody (mAb) against p-AKT was purchased from Cell Signaling Technology. Rabbit polyclonal antibodies against p-JNK, c-Jun and SHIP1, and mouse monoclonal antibodies against b-actin and AKT were obtained from Santa Cruz Biotechnology. The chemical inhibitors SP 600125 and LY 294002 (purchased from EMD Millipore Chemical) were used at the concentration of 20 mM to block the activities of JNK and PI3K-AKT, respectively. Anti-miR-155, Pre-miR155, and the respective negative control inhibitor and mimic were purchased from Ambion. The siRNA for SHIP1 and control sequences were purchased from Santa Cruz Biotechnology. The SHIP1 and control overexpression plasmids were purchased from InvivoGen.

Statistical Analysis
Statistical analysis was performed by Student's t test for two groups of data and by one-way ANOVA for multiple comparisons. Data are expressed as mean 6 SEM from three independent experiments. P,0.05 was considered statistically significant.

Asthmatic Challenges Induce Inflammatory Cytokines in Mouse Lungs
Using a mouse cytokine Multi-Analyte ELISArray Kit (SA-Biosciences), we demonstrated that mice challenged with ovalbumin (OVA) exhibited significant increases of the pro-inflammatory cytokines interleukin 1A, 1B, 4, 5, 6, 8, 12 and 13, and decreases of the anti-inflammatory cytokine interleukin 10 (IL-10) in their bronchoalveolar lavage (BAL) (Fig. 1A). In addition, the airways of these asthmatic mice demonstrated the general features of inflammatory reactions, including the appearance of edematous submucosa, thickening of the basal membrane, increase in epithelial permeability, and recruitment of immune cells to the lung tissue (Fig. 1B). These results indicate the modulations of interleukins in asthmatic responses.

Hyperstretch Modulates Cytokines Secretion in hBECs and hMSCs
It has been shown that hyperstretching human bronchi causes myogenic and inflammatory responses [38]. Our human cytokine array results indicate that the secretions of the inflammatory IL-1A and IL-8 increased significantly in hBECs under the hyperstretch condition of 40 cycles/min and 10% strain ( Fig. 2A). Measurement of IL-8 levels in hBECs with PCR and ELISA showed that the stretch-induced increases of IL-8 mRNA expression (Fig. S1, left panel) and secretion ( Fig 2B) was a time-dependency process during the 24-hour period of study. It is well known that hMSCs serve as excellent immunomodulators both in vitro and in vivo by secreting various cytokines and growth factors, including the antiinflammatory IL-10, to regulate the immune system during inflammation [39,40,41]. Therefore, we tested the regulation of IL-10 expression and secretion in hMSCs and hBECs by hyperstretch. In hMSCs, hyperstretch significantly increased the IL-10 mRNA expression (Fig. S2 right panel) and secretion ( Fig. 2C right panel), but had little effect on IL-8 (Fig. S2, left panel). In hBECs, however, hyperstretch decreased IL-10 mRNA expression (Fig. S1 right panel), but did not significantly alter the IL-10 secretion (Fig. 2C left panel). These results demonstrate that hyperstretch of hBECs induces pro-inflammatory and decreases anti-inflammatory cytokines. In contrast, hyperstretch of hMSCs causes the increase of the anti-inflammatory cytokine secretion.
These findings suggest that hMSCs have a high potential for suppression of inflammation and may potentially rescue the hyperstretch-induced inflammation in hBECs.
hMSCs Suppress Hyperstretch-induced IL-8 Secretion in hBECs via the Paracrine Effect of IL-10 We have used a co-culture system to investigate the interaction between hMSCs and hBECs under hyperstretch (Fig. 3A). In the monocultured hBECs, IL-10 treatment suppressed the IL-8 secretion (Fig. 3B). The IL-8 secretion by hBECs was not significantly altered by co-culture with hMSCs under static condition (Fig. 3B, bars 1 and 5), but was significantly reduced under hyperstretch condition (Fig. 3B, bars 2 and 6). In addition, the hyperstretch-induced hBEC IL-8 secretion can be significantly reduced by the conditioned media from stretched (Fig. S3), but not unstretched (data not shown), hMSCs. The effect, however, is less than that found in direct hMSC co-culture, indicating that the proximity of interaction between hBECs and hMSCs is important for the regulation of inflammatory homeostasis under hyperstretch. Together with the result that hyperstretch induces hMSC IL-10 secretion (Fig. 2C), our findings suggest that hMSCs may become effective for immunosupression under hyperstretch. The blocking antibodies for IL-8, IL-10, and their respective receptors were used to decipher their roles in hMSC-hBEC interaction under hyperstretch. Blocking the IL-8 in the culture medium (Fig. 3C) or the hBEC IL-8 receptor (IL-8R) (Fig. 3D) reduced the hyperstretch-induced IL-8 secretion by mono-cultured hBECs. Blocking IL-8, but not IL-8R, also enhanced the suppressive effect of hMSCs on IL-8 secretion by the co-cultured hBECs. In contrast, blocking IL-10 in the culture medium (Fig. 3E) or the hBEC IL-10 receptor (IL-10R) (Fig. 3F) abrogated the suppressive effect of hMSCs on IL-8 secretion by the co-cultured hBECs. These results indicate that hMSCs suppress hyperstretch-induced inflammation in hBECs via an increased secretion of IL-10, which inhibits IL-8 secretion by hBECs via a paracrine mechanism.
Hyperstretch Increases mirna-155 Production in hBECs and the Reversal of this Effect by Co-culture with hMSCs miRs have been demonstrated to play critical roles in many inflammatory diseases including asthma [19,20], but the roles of miR in mechanical stretch of hBECs and in mechano-pathobiology of the lung remain to be determined. We found that miR-155 was highly expressed in asthmatic mouse lung tissues compared to non-asthmatic normal tissues (Fig. 4A). We further screened inflammatory miRs in hBECs that respond to hyperstretch, and identified miR-155 as being significantly increased by hyperstretch (Fig. 4B).
The hyperstretch-induced miR-155 expression level in monocultured hBECs was abolished by co-culturing with hMSCs ( Fig. 4C) and addition of exogenous IL-10 (Fig. S4), suggesting that miR-155 may play a role in mediating the hyperstretch-induced hBEC-hMSC interaction. Blocking IL-10 (Fig. 4D), and IL-10R (Fig. 4E) also reduced the suppressive effect of hMSCs on miR-155 expression. These results indicate that hMSCs suppress hyperstretch-induced inflammation in hBECs via an increased secretion of IL-10, which inhibits the expression of miR-155 by hBECs via a paracrine mechanism.  IL-10 secretion. In hBEC/hMSC co-culture, however, the hMSCinduced IL-10 secretion is enhanced by the increase of miR-155 with pre-miR155 (Fig. 5E) and abolished by the knockdown of miR-155 with ant-miR155 (Fig. 5F). These results suggest that miR-155 may also be involved in the anti-inflammation pathways in hBEC/hMSC interactions.

miRNA-155 Mediates hBECs Inflammation through SHIP1
The above results showed that miR-155 is involved in the hyperstretch-induced inflammation by modulating the responses in hBECs. However, the detailed mechanism by which miR-155 mediates hBECs inflammation remains unknown. Previous studies have shown that SHIP1 is a potential target during inflammation [42,43]. We first tested the role of miR-155 in hyperstretchregulation of SHIP1 expression. Knockdown miR-155 with anti-miR-155 attenuated the hyperstrech-suppression of SHIP1 levels (Fig. 6A). Overexpression of miR-155 with pre-miR-155 caused a decrease of SHIP1 level in hBECs under static condition (data not shown), but it had little effect on the stretch-reduction of SHIP1 (Fig. 6B). Using hSHIP1 39UTR luciferase constructs with wild type (WT) or mutant (MUT) miR-155 target sequences, we demonstrated that hyperstretch down-regulated WT, but not the mutant, hSHIP1 39UTR luciferase in hBECs. The addition of anti-miR-155 abolished the hyperstretch-suppression of WT- hSHIP1 39UTR-luciferase activity (Fig. 6C). These results suggest that miR-155 directly targeted SHIP1 to regulate hBEC signaling under hyperstretch.

Overexpression of SHIP1 in hBECs Reversed the Stretchinduced miR-155 Level
SHIP1 has been shown to be an upstream regulator for MAPK [44] and PI3K [45,46,47] pathways. We investigated the miR-155/SHIP1 downstream signaling events that lead to hyperstretch-regulated signaling events by overexpressing and knocking down the endogenous SHIP1 in hBECs under hyperstretch. Overexpression of SHIP1 rescued the hyperstretch-suppression of SHIP1, and therefore, attenuated the stretch-induced inflammatory signaling activation, including the phosphorylations of JNK (Fig. 7A) and AKT (Fig. S5A). Knockdown SHIP1 with siRNA increased the phosphorylations of JNK and AKT under static condition, but not under the hyperstretch condition (Figs. 7B and S5B) in which the SHIP1 level was already low (Fig. 7B). The functional role of hyperstretch-regulated SHIP1 in hBEC inflammation was also confirmed by testing the effects of SHIP1 modulation on hBEC IL-8 secretion and miR155 expression. Knockdown SHIP1 in hBECs with siRNA had little effect on miR-155 expression (Fig. 7C) and IL-8 secretion (Fig. 7D), but SHIP1 overexpression negatively regulated miR-155 expression (Fig. 7C) and IL-8 secretion (Fig. 7D) in hBECs under hyperstretch. The inhibition of JNK led to the reductions of hBEC miR-155 expression (Fig. 7E) and IL-8 secretion (Fig. 7F), but these effects are not seen with AKT inhibition (Fig. S6), suggesting that miR155-SHIP1-JNK may play an important role in the hyperstretch-induced hBEC inflammatory responses. Based on these in vitro observations, we examined the expression of miR-155 and SHIP1 in lung tissues of normal and asthmatic mice in vivo. Indeed, the miR-155 expression level was elevated in asthmatic samples (Fig. 7G), and the SHIP1 expression was significantly lower than in the asthmatic samples than normal control. Thus, our results indicate that miR-155 expression is significantly induced under hyperstretch in asthmatic lung to repress SHIP1 expression and induce the inflammatory signaling in hBECs. The finding that the expression of miR-155 can be attenuated by SHIP1 overexpression suggests a potential therapeutic role of SHIP1 in mitigating pulmonary inflammation.

Discussion
Asthma is a disease of airway dysfunction that involves epithelial damages, bronchoalveolar lavage fluid mediator accumulation, increased cytokine secretion, and epithelial hyperplasia [48]. There is increasing evidence that mechanical forces, including stretching, act on lung cells to affect their structure, function, metabolism, and signaling [1,2,3,8,9,10]. In asthma patients with increased respiration rates, the lung is subjected to stretch beyond that during normal respiration [4,5], and the hyperstretch in asthma attacks tends to worsen the airway obstructions [11,12] via myogenic and pulmonary inflammatory responses [13]. The acute responses (within 5 min) of hyperstretch-induced human bronchi inflammation involves NOS activation, and Rho, Wnt signaling [13]. However, the impact of long-term hyperstretch, as in asthmatic lung, on pulmonary responses remains undetermined. In the current study we investigated the mechanisms by which 24hour hyperstretch regulates pulmonary cell inflammatory reactions. Our in vitro studies on cultured hBECs subjected to 24-hour hyperstretch and in vivo studies on bronchoalveolar lavage from 3-4 week OVA-induced asthmatic mice have shown increased expressions of pro-inflammatory cytokines such as IL-8 and decreased expressions of the anti-inflammatory cytokine IL-10 ( Figs. 1 and 2). Our results demonstrated that asthmatic lung significantly increases the secretion of multiple interleukins, including IL-1A, 1B, 4, 5, 6, 8, 12, 13 (Fig. 1B), while in vitro hyperstretch only significantly induced IL1A and 8. The discrepancy of the results may be partially due to the difference in experimental duration, i.e., the asthmatic mice were under challenge for 3-4 weeks, while hyperstretch only lasted for 24 hr. In addition, it is likely that the in vivo environment involves multiple cell types which may modulate the responses, while in vitro hyperstretch only acted on the epithelial cells. Nevertheless, the in vitro hyperstretch system has provided the evidence that hyperstretch induces pulmonary cell inflammatory responses within 24 hours. Such a system allows us to further decipher the molecular mechanisms of hyperstretch responses of hBECs, as well as their interactions with hMSCs.
hMSCs have been recognized as an excellent immune moderator both in vivo [35,49,50] and in vitro [51,52] by secreting a repertoire of anti-inflammatory cytokines such as IL-10 to suppress inflammation [49] in response to various mechanical forces [53,54]. We modified the in vitro co-culture stretch camber (Fig. 3A) to study the interactions between hMSCs and hBECs under hyperstretch. Our results demonstrated that the hyperstretch-induced IL-8 secretion by hBECs can be suppressed by coculture with hMSCs and by using the conditioned media from stretched hMSCs. The suppression effect was abrogated by blocking IL-10 in the culture medium or the IL-10R on hBECs and enhanced by blocking IL-8 or IL-8R, These findings indicate that hMSCs suppress hyperstretch-induced inflammation in hBECs via a paracrine mechanism.
MiRs act as critical regulators of gene expression and cellular functions in health and disease. A recent study on profiling miR expression in asthmatic mice demonstrated the elevated levels of multiple miRs, including the ones related to inflammatory responses [55]. In screening inflammatory miRs in hBECs that respond to hyperstretch, we identified miR-155 is significantly increased by hyperstretch (Fig. 4B). The hyperstretch-induced miR-155 expression, as the IL-8 secretion, in mono-cultured hBECs was abolished by co-culturing with hMSCs. Figs. 3E and 3F showed that the hMSCs suppression of hBECs inflammation is mediated by IL-10. Recent study showed that IL-10 inhibits LPSinduced miR-155 expression [56,57]. The study supports our results that IL-10 mediates the hMSC suppressive effect on hBEC inflammation via inhibition of miR-155. We also found that the hyperstretch-inductions of miR155 and IL-8 in hBECs were enhanced by pre-miR-155 and mitigated by anti-miR-155 (Fig. 4). In hBECs, the secretion level of IL-10 was not affected by pre-miR-155 and anti-miR-155 ( Fig. 5E and 5F). In hMSCs, however, the IL-10 secretion was significantly up-regulated by pre-miR-155 and down-regulated by anti-miR-155, indicating that miR-155 augments IL-10 production by hMSCs during hyperstretchinduced inflammation Together with the finding that IL-10 mediates the hMSC suppressive effect via inhibition of miR-155 (Figs. S4, 4, and 5), these results suggest a negative feedback in which an increase of miR-155 would stimulate the release of IL-10 to decrease miR-155 and hence the inflammatory response. However, the mechanism by which hyperstretch induces miR-155 expression remain unclear. Recent studies suggest that expression of miR-155 in cancer growth and inflammation can be regulated by a variety of receptors and transcription factors, including TLR4 and AP-1 [58] and that IL-10 inhibits miR-155 by blocking the TLR4 signaling [59]. Mechanical stretch has been shown to modulate the activities of those molecules [60]. Further investigations are needed to further eluidate the molecular mechanism by which hyperstretch regulates IL-10/miR-155 signaling in hBEC inflammation.
MiR-155 is involved in many important biological processes [61], and it has been identified to play a critical role in modulating the crosstalk in cancer and inflammation [62]. More importantly, miR-155 has been shown to be a potential pro-inflammatory regulator in lung diseases [63]. Src homology 2 domaincontaining inositol 5-phosphatase 1 (SHIP-1) is a primary target of miR-155 during inflammation [42,43], we tested the role of miR-155 in hyperstretch regulation of SHIP1 expression. SHIP1 expression was down-regulated by hyperstretch, and this was reversed by anti-miR-155 in hBECs. SHIP1 overexpression negatively regulated miR-155 expression and IL-8 secretion in hBECs under hyperstretch in vitro. The induction of miR-155 and reduction of SHIP1 in lung tissues were confirmed in asthmatic mouse over normal controls in vivo (Fig. 7E), which is similar to the responses of miR-155 and SHIP1 in hBECs under hyperstretch in vitro. These results indicate that miR-155 represses SHIP1 expression and induces the inflammatory signaling both in vitro and in vivo. Furthermore, the finding that overexpression of SHIP1 attenuated hyperstretch-induction of miR-155 suggests a potential feedback mechanism for an anti-inflammatory role of SHIP1.
Further investigations are needed to establish the interaction between SHIP1 and miR-155 in greater detail.
It has been shown that hyperstretch induced epithelial IL-8 expression through the JNK/NFkB pathway [64], and that miR-155 suppresses SHIP to activate AKT pathway to promote inflammation in lung epithelial cells [65]. Consistent with these findings in the literature, our results demonstrate that hyperstretch induces miR155 to suppress SHIP1, thus leading to the activation of JNK and AKT pathways (Figs. 7A, 7B, and Fig. S5). In addition, the addition of exogenous IL-10 attenuated the stretchinduced JNK and AKT phosphorylation, while overexpression of pre-miR155 induced JNK and AKT phosphorylation (data not shown). However, only the inhibition of JNK (Fig. 7), but not AKT (Fig. S6), attenuated the hyperstretch-induced inflammation in hBEC. In summary, our results indicate that hMSC co-culture suppresses the hyperstretch-induced inflammation by secreting IL-10 to inhibit the miR-155-SHIP-JNK signaling (Fig. 8). Although hyperstretch is not the only factor that causes inflammation in the asthmatic mouse model, our data shed new insights on how miR-155 mediates the hMSC-regulation of inflammation and reveal the therapeutic potentials of hMSCs and miR-155 for the treatment of asthma and related lung diseases.
The current study, by integrating biomechanics, vascular biology, and systems biology approaches, have contributed to the understanding of the roles of hMSCs and miR-155 in regulating hBEC functions in response to hyperstretch. We have established the molecular and mechanical bases of hyperstretchregulation of miR-155 in mono-cultured hBECs and hBEC/ hMSC co-culture, and the consequent gene modulation and functional manifestation. For the first time, we successfully developed a mechanical stretch co-culture platform to investigate the interactions between different cell types under stretch condition. This study has elucidated the molecular basis of hBEC/hMSC interaction under hyperstretch that is relevant to the pathophysiology of asthma.